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Abstract Sacral neuromodulation isincreasingly usedfor the
treatment of voiding dysfunction, pelvic pain syndromes, and
gastrointestinal disorders. While increased use of this technol-
ogyhasledtoagreaterunderstandingofitspotentialaswellas
its limitations,difficultypersists inidentifyingthe patientsthat
will benefit most. Either of two trial stimulation techniques is
performed before placement of a permanent neuromodulator:
the monopolar percutaneous nerve evaluation and the tined
quadripolarstagedtrial.Thepreponderance ofrecentliterature
asserts the superior sensitivity of the staged trial over
percutaneous nerve evaluation. However, the techniques offer
disparate advantages, and other issues, such as cost-
effectiveness, remain largely unexplored. The role of sacral
neuromodulation will continue to expand as physicians and
patientsbecomeincreasinglyawareofitstherapeuticpotential.
Widespread adoption of this clinically superior technique will
most rapidly help the greatest number of patients.
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Introduction
Sacral neuromodulation (SNM) is a vitally useful alterna-
tive therapy for many patients with a variety of refractory
voiding dysfunctions. In 1997, the U.S. Food and Drug
Administration (FDA) approved SNM for urgency inconti-
nence, and in 1999 for refractory urgency–frequency syn-
drome and nonobstructive chronic urinary retention [1, 2].
Non-FDA approved uses are also increasing. Several
investigators report significant benefits of neuromodulation
for pelvic pain disorders, fecal incontinence, fecal retention,
and pediatric voiding dysfunction. While the exact mecha-
nism of action is unknown, neuromodulation is thought to
alter the pathological imbalance of sacral reflexes controlling
bladder storage and emptying. Because it is difficult to
predict therapeutic response, a trial phase of SNM is
performed before placement of the implantable pulse
generator (IPG). Two different testing methods are widely
used and their relative value debated: the percutaneous nerve
evaluation (PNE) and the staged implantation using perma-
nent leads. This review discusses the relative merits of each




The traditional PNE is an office-based technique that uses a
temporary monopolar lead without an intrinsic retention
mechanism, allowing for minimally traumatic deployment
and retrieval. Most commonly, the lead is placed bilaterally
via the S3 foramen under local anesthesia without the
assistance of fluoroscopy. Correct lead placement is
determined by a levator ani motor response, plantar flexion
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DOI 10.1007/s11934-010-0128-2of the ipsilateral great toe, and induction of perineal sensory
activation [3]. Some groups advocate subsequent stimulation
of the next caudal foramen to assess for S2 stimulated leg
rotation, thereby offering additional confirmation of appro-
priate S3 placement of the test lead. The temporary lead is
retained for the duration of the test phase by fixation to the
skin surface with adhesive. The test phase is usually 4 to
7 days, limited primarily by lead migration and the patient’s
ability to restrict activity. PNE lead migration is particularly
problematic among obese and active patients [3]. Following a
successful test phase, the temporary lead is easily withdrawn
(as well as any therapeutic effect), and the patient is taken to
the operating room for fluoroscopically guided insertion of a
permanent quadripolar tined lead and IPG in one setting. The
device is then programmed, hoping to duplicate or improve
upon the response to the temporary lead.
Staged Implantation
The staged implantation technique was first described in
1997 [3] in response to those patients that initially failed a
PNE trial. This technique most commonly involves fluoro-
scopically guided unilateral placement of a permanent
quadripolar tined lead in the operating room with the
patient under sedation. Formerly, the lead lacked an
intrinsic retention mechanism and was secured to the
dorsolumbar fascia to decrease the rate of lead migration.
This method of lead fixation was supplanted by the
development of a self-retaining quadripolar tined lead in
2003 [4]. Intraoperative bipolar testing can be performed
with the permanent lead, though it is not widely practiced.
As with the PNE lead, intraoperative testing is typically
performed with monopolar stimulation seeking a levator ani
and ipsilateral great toe motor response and perineal
sensory stimulation. While a suboptimal response to intra-
operative monopolar stimulation may preclude placement
of a PNE lead, this is not the case with a quadripolar lead.
Postoperatively, the quadripolar lead affords far greater
programming versatility as compared to the monopolar
temporary lead, and thus, higher likelihood for therapeutic
effect. Additional program options may be gained by
placement of a second, contralateral, quadripolar lead. The
permanent lead is then connected to extension wires that are
tunneled through the subcutaneous tissue, further mitigating
the risk of lead migration and infection [5￿, 6]. In contrast
to the PNE lead, the incidence of lead migration is
significantly reduced with these maneuvers, though cases
of tined lead migration are reported [7]. The test phase may
be extended as long as several weeks while optimizing
programming [5￿]. If the test phase produces significant
improvement in the symptoms, the patient is brought back
to the operating room and the IPG is placed. The original
quadripolar leads are not moved, and the demonstrably
successful test settings may be immediately programmed
into the permanent device for uninterrupted treatment.
Test Phase Response Differs by Technique: Analysis
by Clinical Indication
Subjective Response in Voiding Dysfunction
Patients reporting at least 50% improvement in symptoms
during the test phase are traditionally considered a success.
Whilethiscriterionisarbitrary,itisacommonlyusedsurrogate
to define success in both PNE and staged trials. Regardless,
patients receiving the IPG implantation following a similarly
defined successful trial, whether PNE or staged, may have
similar long-term therapeutic benefit [6]. This suggests similar
specificity among the two techniques. Thus, a sensitive
endpoint in determining the relative merits of staged versus
PNE trials is progression rate to IPG implantation.
Several groups demonstrated that staged trials have a
greater rate of IPG implantation among neuromodulation-
naïve patients. In 2008, Bannowsky et al. [8￿] reported their
experience with SNM in patients with voiding dysfunction.
In their study, 42 patients received bilateral PNE and 11
received bilateral tined leads. 82% of staged patients
progressed to IPG placement, while only 47% of patients
receiving PNE progressed to permanent implantation. Hijaz
et al. [9] reported a progression from staged trial to IPG
implantation in 161 of 214 patients (75.2%), though 14.6%
of these patients were treated for interstitial cystitis.
Blandon et al. [10] recently described their experience of
105 test procedures in 95 female patients with voiding
dysfunction. Thirty patients underwent PNE and 75 patients
received staged leads, 11 of which predated the tined lead and
were instead anchored to the dorsolumbar fascia. The final 64
patients received self-retaining tined leads. The staged leads
afforded a longer screening time of 3.4 weeks versus
1 week for PNE. Of patients receiving tined leads, 67%
progressed to IPG implantation compared to 36% of patients
with leads anchored to fascia and 40% of patients receiving
PNE (P=0.01). Another study evaluated 30 patients aged
55 years and older with refractory urge incontinence
randomized to either PNE or a staged technique [11￿￿]. The
likelihood of progressing to IPG was significantly greater in
the staged cohort (15 of 17 patients; 88%) compared to the
PNE group (6 of 13 patients; 46%).
Additionally, many patients failing a PNE test will
respond to a staged trial and proceed to IPG placement. In
2007, Siegel’s group [12￿] reported on their considerable
11-year experience of 155 leads in 104 patients. Eighty-two
nontined leads were placed after PNE trial and 73
quadripolar tined leads were implanted as part of a staged
procedure. Seventeen of 28 patients failing the first trial and
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PNE. Similarly, four of five patients requiring a third trial
finally found success with a tined staged implant, and all
five patients undergoing a fourth trial ultimately found
success following a tined staged implant.
Based on our review, IPG implantation rates, as
predicated on patient-defined symptom improvement, ap-
proach 40% to 50% in PNE and 70% to 90% in tined-lead
staged trials. The lower rate of PNE progression to IPG
implantation can be attributed to several factors. First,
monopolar PNE programming is limited to changes in pulse
width, frequency, amplitude, and either continuous or
intermittent stimulation. In contrast, quadripolar leads have
greater range of programming options with a variety of
stimulation patterns. The staged technique exploits this
advantage to the patient’s benefit. Second, there is a
significant incidence of PNE lead migration. The true rate
of migration is unknown because imaging is not routinely
performed for all PNE failures. A novel PNE tunneling
technique that reduces PNE lead migration and confers
greater progression to IPG implantation is described.
However, it is unclear how many surgeons have adopted
this modification [13]. Finally, these limitations shorten the
PNE trial phase duration, thus further limiting the trial
phase to observe any potential benefit of neuromodulation.
Unilateral Versus Bilateral Test Phase
Though several articles address the issue of unilateral
versus bilateral stimulation, the comparative efficacy is
not well studied and conflicting evidence abounds. In their
series of 20 patients with voiding dysfunction, Kessler et al.
[6] found that the only 2 long-term failures among 16
permanent placements occurred in patients with unilateral
stimulation. In contrast, Scheepens et al. [14] noted no
significant difference in progression to second stage or
long-term outcome between unilateral and bilateral non-
tined temporary leads in patients with voiding dysfunction.
A retrospective comparison of 55 patients undergoing
unilateral test stimulation versus 69 patients undergoing
bilateral test stimulation respectively for refractory voiding
dysfunction revealed greater progression to permanent
implant in the bilateral group (76%) compared to the
unilateral group (58%) [15]. Although bilateral stimulation
may offer more programming flexibility, it remains to be
seen whether this translates to superior clinical effect.
Attempts to Quantify Response Based on Testing
Technique
In an effort to objectively measure a physiologic difference
between the two trial methods, Bannowsky et al. [8￿]
performed urodynamic studies on 30 patients with urinary
retention and 23 with overactive bladder (OAB) syndrome
during the testing phase. All but one patient underwent
bilateral stimulation. Conventional PNE was received by 42
patients (25 in retention, 17 with urgency–frequency) while
11 patients (5 in retention, 6 with urgency–frequency)
underwent a staged trial.
All patients underwent preoperative and postoperative
voiding diaries and videourodynamics. Both PNE and
staged implantation groups improved in reduction of pad
consumption and urge episodes. Among the patients with
OAB, bladder capacity was increased by 30% with PNE
and 52% with staged trials, while capacity at first urge was
significantly improved only in the staged cohort. Both PNE
and staged trials decreased detrusor instability by about
75%. Patients with nonobstructed urinary retention also
fared better with the staged implantation technique. They
demonstrated greater increase in maximum detrusor pres-
sure (94%) over baseline, and 66% reduction in residual
urine allowing for either voluntary micturition or reduction
in catheterization frequency. Overall, they observed a
permanent implantation rate of 47% among patients
receiving PNE and significantly greater (82%) in staged
implantation. While they retrospectively describe a hetero-
geneous nonrandomized cohort, the findings suggest a
more robust response following the staged trial technique.
Comparison of Techniques in Interstitial Cystitis,
Painful Bladder Syndrome, and Chronic Pelvic Pain
Since neuromodulation safety and efficacy first were
established 10 years ago for voiding dysfunction, we have
witnessed a surge of its utilization for various pelvic
disorders. While not FDA-approved for these indications,
many patients with refractory interstitial cystitis (IC),
painful bladder syndrome (PBS), and chronic pelvic pain
(CPP) now benefit from SNM and caudal epidural neuro-
modulation [16￿, 17]. Similar to the voiding dysfunction
patient population, the most optimal test modality has not
been established for this patient population.
Peters et al. [17] reported outcomes of 21 patients with
IC following bilateral PNE placement with confirmed
motor and sensory responses during a 5 to 7 day test
period. Of these patients, 14 (67%) had a positive response,
11 of whom (79%) progressed to the permanent lead
placement, with a total implant rate of 52%. It is important
to note that 100% of patients who had the permanent
implant placed under sedation and confirmed sensory
response did not require further reoperations or adjust-
ments, whereas up to 43% patients who underwent
implantation without sensory response verification required
reoperation for lead adjustment and pocket revision. This
suggests the importance of intraoperative confirmation for
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also reported on 16 patients with IC receiving the unilateral
staged technique with motor and sensory response confir-
mation following a 2-week testing period. All but one
patient (94%) selected permanent generator placement and
no reoperations were performed.
Another study reported similarly improved progression to
IPG with the staged technique [18￿￿]. In this study, 13 of 33
patients (39.4%) undergoing temporary PNE in the office
progressed to the second stage, while 9 of 11 (81%)
evaluated by staged quadripolar lead completed IPG implan-
tation, including 5 who previously had failed PNE testing.
Regardless of test modality, long-term success was equiva-
lent among patients selecting permanent implantation.
Reproducibility of test-phase efficacy following IPG
placement may also differ by technique among patients
treated for pelvic pain disorders. One series reported as
many as 33% of patients lost efficacy when the permanent
lead and IPG were placed following a successful PNE trial,
whereas in a staged trial, the therapeutic effect was
maintained in all but 14% [19].
It is unclear whether there is an advantage to either
unilateral or bilateral neuromodulation in patients with
pelvic pain syndromes. It seems logical to offer bilateral
stimulation to patients with bilateral symptoms. Moreover,
based on some reported series, bilateral stimulation may
afford greater efficacy to patients with truly refractory
pelvic pain syndromes. The paucity of data in this difficult-
to-treat patient population with chronic refractory disorders
underscores the need for properly designed clinical trials to
fully explore the efficacy of various SNM programming
parameters and implantation techniques.
Cost
While there is evidence that SNM is cost-effective for
pharmacologically refractory voiding dysfunction as com-
pared to either botulinum toxin injections or noninterven-
tion [20￿￿, 21], we are unaware of any cost-effectiveness
analysis comparing PNE to staged implantation.
The 2009 Medicare reimbursement in Los Angeles, CA
differed significantly based on implantation technique and
facility. Unilateral staged implantation performed in the
operating room reimbursed $742.73 with subsequent IPG
paying $1055.85 for a total compensation of $1798.58.
Unilateral office-based PNE trial reimbursed $1792.62,
and, if successful, an additional $1055.85 for the IPG
placement for a total of $2848.47.
Medicare clearlyincentivizes theproliferationoftheoffice-
based PNE over the staged procedure. It may be argued that
this remuneration structure unnecessarily increases Medicare
costs and promotes abuse of a less sensitive intervention.
Alternatively, it may be argued that the widespread use of the
less expensive PNE electrode exposes a greater number of
medically refractory patients to potentially beneficial treat-
ment. A formal cost–benefit analysis has not been reported
andshouldbeundertakentoanswertheseimportantquestions.
Conclusions
We believe the preponderance of evidence clearly supports
the superiority of staged evaluations as compared to the
traditional PNE. Staged trials have a lower incidence of
lead migration, and thus a prolonged trial phase. This
allows for the exploration of varying and more sophisticated
programming and greater progression to IPG implantation.
Staged trials offer uninterrupted treatment before IPG
placement and, because the trial lead is not removed,
conservation of successful trial settings. Well-designed
comparative studies evaluating unilateral versus bilateral
stimulation and various programming options are needed to
fully explore SNM as a treatment modality for various
refractory voiding dysfunction and pelvic pain syndromes.
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